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The phosphatidylinositol-3-kinase (PI3K)/Akt signalling pathway is frequently deregulated in pancreatic cancers, and is believed to be
an important determinant of their biological aggression and drug resistance. NVP-BEZ235 is a novel, dual class I PI3K/mammalian
target of rapamycin (mTor) inhibitor undergoing phase I human clinical trials. To simulate clinical testing, the effects of NVP-BEZ235
were studied in five early passage primary pancreatic cancer xenografts, grown orthotopically. These tumours showed activated
PKB/Akt, and increased levels of at least one of the receptor tyrosine kinases that are commonly activated in pancreatic cancers.
Pharmacodynamic effects were measured following acute single doses, and anticancer effects were determined in separate groups
following chronic drug exposure. Acute oral dosing with NVP-BEZ235 strongly suppressed the phosphorylation of PKB/Akt, followed
by recovery over 24h. There was also inhibition of Ser235/236 S6 ribosomal protein and Thr37/46 4E-BP1, consistent with the
effects of NVP-BEZ235 as a dual PI3K/mTor inhibitor. Chronic dosing with 45mgkg
 1 of NVP-BEZ235 was well tolerated, and
produced significant tumour growth inhibition in three models. These results predict that agents targeting the PI3K/Akt/mTor
pathway might have anticancer activity in pancreatic cancer patients, and support the testing of combination studies involving
chemotherapy or other molecular targeted agents.
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Aberrant signalling by phosphatidylinositol-3-kinase (PI3K) is a
prominent feature of pancreatic cancers, due to the high
prevalence of abnormalities that regulate this pathway, including
K-ras mutations that occur in approximately 90% of cases,
increased expression of receptor tyrosine kinases like EGFR, and
loss of PTEN (Korc, 1998; Ruggeri et al, 1998; Bardeesy and
DePinho, 2002; Agbunag and Bar-Sagi, 2004; Asano et al, 2004;
Chadha et al, 2006). The activation of downstream survival
signalling pathways likely has an important role in the aggressive
clinical features of pancreatic cancer, including resistance to
chemotherapy. This is supported by recent results from a
randomised clinical trial that showed a modest but significant
improvement in patient survival when the EGFR inhibitor erlotinib
was combined with the standard chemotherapy agent gemcitabine
(Moore et al, 2007). Furthermore, we have previously shown that
treatment with the natural product wortmannin resulted in
decreased PKB/Akt phosphorylation in an orthotopic xenograft
model of pancreas cancer, consistent with PI3K inhibition, and
that combined treatment with wortmannin and gemcitabine
resulted in greater acute induction of apoptosis, and improved
tumour growth inhibition, compared to gemcitabine alone
(Ng et al, 2001).
NVP-BEZ235 is a novel imidazoquinoline derivative that shows
high selectivity for class I PI3K and the structurally related
mammalian target of rapamycin (mTor; Maira et al, 2008). It has
pharmacological properties that allow it to be tested for anticancer
effects in vivo, and is well tolerated at dose schedules that result in
decrease phosphorylated levels of the downstream target PKB/Akt.
Furthermore, continuous oral dosing schedules with NVP-BEZ235
are growth inhibitory in human tumour xenograft mice and rat
models (Maira et al, 2008).
In agreement with the experience from other groups, we have
previously shown that primary xenografts can be established from
the majority of pancreatectomy specimens and that when grown at
the orthotopic site, they show typical histological features of
pancreatic cancer (Ng et al, 2002; Rubio-Viqueira et al, 2006).
These tumours therefore offer the opportunity for the near-clinical
testing of novel molecular targeted agents in a controlled
laboratory setting that allows detailed analysis of the relationships
between the tumour characteristics, pharmacological effects, and
anticancer activity. In the present paper we tested the effects
of NVP-BEZ235 in a series of five early passage primary
pancreatic cancer xenografts, and show that acute oral single
doses suppress signalling targets downstream from PI3K/mTor in
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sa time-dependent manner consistent with the pharmacokinetics of
the compound, and that chronic treatment produces significant
growth inhibition.
MATERIALS AND METHODS
Establishment of primary pancreatic cancer xenografts
Animal experiments were carried out using protocols approved
by University Health Network Animal Welfare Committee. The
establishment of the primary pancreatic cancer xenografts was
carried out as previously described (Ng et al, 2002; Yau et al, 2005).
Fresh pancreatic cancer samples that were superfluous to
diagnostic needs were obtained from the University Health
Network Tumour Tissue Bank according to institutional human
ethical guidelines. Tumour fragments were initially implanted
subcutaneously into the flanks of male SCID mice. Primary
xenografts established from this material were subsequently
transferred to the orthotopic site of 4- to 5-week-old mice by
attaching tumour pieces from the previous passage to the surface
of the exposed pancreas, by a small incision under general
anaesthesia. Five primary pancreatic cancer xenografts, designated
OCIP16, 17, 18, 19, and 21, were used at passage number 4–6 for
these experiments.
Characterisation of primary xenografts
Once sufficient tumour tissue was available, typically at passage
number two or three, orthotopic tumours were rapidly excised and
divided into roughly similar pieces. One of these was processed for
protein extraction, one was snap frozen in liquid nitrogen, and one
was fixed in formaldehyde followed by paraffin embedding. Cut
tissue sections were stained with haematoxylin and eosin (H&E)
for morphological assessment, and by immunohistochemistry for
relevant protein markers including surface receptor tyrosine
kinases and SMAD4 using appropriate primary antibodies. Codon
12/13 K-ras mutations were determined by gene sequencing.
Activation of intracellular signalling proteins was assessed by
immunohistochemistry using the following phosphospecific anti-
bodies: Ser473 PKB/Akt; rabbit monoclonal obtained from Cell
Signaling Technology (CST, Danvers, MA, USA); phosphorylated
extracellular-regulated kinase (ERK) 1/2 (mouse monoclonal;
CST). Signal transduction and activator of transcription (Stat) 3,
Tyr705 (mouse monoclonal; CST) and Ser727 (rabbit polyclonal;
CST). Tumour morphology was assessed by a pathologist, and the
intensity of immunohistochemical staining for each of the tumour
markers was scored from 0 (absent staining) to 3þ (strong
staining).
Drug treatment
NVP-BEZ235 (Figure 1) was obtained from the Oncology
Department of the Novartis Institutes for Biomedical Research in
Basel, Switzerland. Fresh stock solutions of the compound were
prepared daily by dissolving in 1 volume of NMP (1-methyl-2-
pyrrolidone; Sigma-Aldrich, Oakville, Ontario, Canada) in a 1001C
water bath, then adding 9 volumes of PEG300 (Sigma-Aldrich) to
give a final drug concentration of 12.5mgml
 1.
To monitor the acute pharmacodynamic effects of NVP-BEZ235,
five groups each of three randomly assigned tumour-bearing mice
were treated with 50mgkg
 1 NVP-BEZ235 by oral gavage and
killed at 0, 2, 4, 8, and 24h. The tumours were rapidly excised and
divided into pieces that were snap frozen in liquid nitrogen, or
fixed in formaldehyde and then were paraffin-embedded, or
processed for protein extraction.
To assess the anticancer effects, the NVP-BEZ235 dose was
reduced to 45mgkg
 1, q.d., which is a dose and schedule that have
been shown to be efficacious in in vivo mouse xenograft human
cancer models (Maira et al, 2008). Two groups of 10–12 randomly
assigned tumour-bearing mice were treated with NVP-BEZ235 or
the vehicle control given by oral gavage daily for 5 days per week.
Treatment commenced when the tumours were just palpable, and
the duration was 3–5 weeks according the rates of tumour growth
for the different models. The mice were monitored three times
weekly by body weight and abdominal palpation, and for signs of
distress, and killed according to animal welfare guidelines if they
showed 410% loss of body weight or other signs of significant
distress due to tumour growth or treatment toxicity. At the end of
treatment the animals were killed and the tumours were harvested
and weighed after removal of non-tumoural tissues. The tumours
were then processed for further analysis, similar to the acute
single-dose series.
Measurement of NVP-BEZ235 effects
The pharmacodynamic effects of acute single doses were
investigated by western blot and ELISA analyses of the tumour
lysates. Minced tumour pieces were homogenised in 1ml lysis
buffer (50mmoll
 1 HEPES (pH 8.0), 10% glycerol, 1% Triton
X-100, 150mmoll
 1 NaCl, 1mmoll
 1 EDTA, 1.5mmoll
 1 MgCl2,
100mmoll
 1 NaF, 10mmoll
 1 NaP2O7KH2O, 1mmoll
 1 NaVO4)
containing protease inhibitor cocktail tablets (Roche Canada,
Mississauga, Ontario, Canada) for 1h on ice. Homogenates were
clarified by centrifuging at 14000r.p.m. at 41C for 15min. Samples
were then heated in sample buffer for 10min at 951C, run on 10%
SDS–polyacrylamide gels, and transferred to PVDF membranes
using the Mini Trans-Blot Electrophoresis Transfer Cell (Bio-Rad
Laboratories, Mississauga, Ontario, Canada). Membrane blots were
blocked for 1h at room temperature with 10% BSA in TBS with 1%
Tween 20 and then incubated overnight at 41C with the following
primary phosphospecific antibodies: Ser473 PKB/Akt (rabbit
monoclonal from CST, 1:500 dilution), Ser21/9 GSK3 a/b
(rabbit polyclonal from CST, 1:1000), Ser235/236 S6 ribosomal
protein (CST; 1:7000) and Ser240/244 S6 ribosomal protein (rabbit
polyclonal (CST; 1:1000), Thr37/46 4E-BP-1 (CST; 1:1000), Ser727
Stat3 (CST; 1:1000), and Tyr705 Stat3 (CST; 1:1000). The loading
control was anti-actin (1:7000; Abcam, Cambridge, MA, USA).
Following overnight incubation with the primary antibody, the
blots were probed with either anti-rabbit polyclonal or anti-mouse
monoclonal secondary antibodies labelled with horseradish
peroxidase (GE Healthcare Biosciences Inc. Baie d’Urfe, Quebec,
Canada) and then exposed to SuperSignal West Pico Chemilumi-
nescent Substrate (Fisher Scientific, Ottawa, Ontario, Canada)
according to the manufacturer’s instructions.
To assess the effects of chronic drug administration on
angiogenesis, proliferation, and apoptosis, paraffin-embedded
sections of tumour tissues were stained by immunohistochemistry
using antibodies to CD31, cyclin D1, p27, and cleaved caspase 3.
The slides were then scanned using a ScanScope CS
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Figure 1 Structure of NVP-BEZ235.
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s(Aperio Technologies Inc., Vista, CA, USA). Digital image analysis
was carried out using the Aperio software, based on 10 fields of
view of the tumoural area for each section, at  10 magnification.
Analytical procedure for quantification of BEZ235
Quantitative analysis of tumour samples for BEZ235 was
performed with an HPLC/dual mass spectrometry (MS/MS)
method. To each gram of tissue 1ml of phosphate-buffered saline
was added. The tissues were homogenised using an ULTRA-
TURRAX (TP18-10; IKA, Staufen, Germany) homogeniser, keeping
the material during the homogenisation as cold as possible by
returning the homogenate to an ice bath between short
(approximately 15s) bursts. Proteins in tissue homogenate were
precipitated by the addition of an equal volume of acetonitrile and
processed further for chromatographic separation as described
below. Stock solutions of the analyte BEZ235 (MW 469.6) and the
structurally related internal standard (IS, MW 476.6) were
prepared fresh daily at a concentration of 10mgml
 1 (analyte)
and 1mgml
 1 (IS) in methanol/water (2:9, v/v). Further
dilutions were prepared in the same solvent. Calibration samples
were prepared in pooled homogenates of the corresponding
tumours obtained from untreated animals. Tumour homogenate
(25ml) was mixed with appropriate amounts of BEZ235 to deliver a
nominal final concentration of 10–2000ngml
 1. The quality
control (QC) samples were spiked with the analytes to give a final
concentration of nominally 40, 100, 400, and 1600ngml
 1
respectively. A 50ml aliquot (1mgml
 1) of the IS was added to
each calibration standard and to the QC samples and mixed on a
vortex mixer for 15s. After three times repeated protein
precipitation by addition of an equal volume of acetonitrile
followed by evaporation to dryness, the samples were re-dissolved
in 100ml acetonitrile/water (1:9, v/v) containing 0.2% v/v formic
acid. Sample injection volume was 5ml for the chromatographic
separation.
The liquid chromatographic separations were carried out using
an Agilent 1100 Series (Agilent, Palo Alto, CA, USA) HPLC system
with vacuum degasser, capillary pump, and thermostated column
compartment (401C) combined with an automated injection device
OCIP16
500 m
OCIP17
OCIP18
OCIP19
OCIP21
PKB/Akt Ser473 H&E
Figure 2 Histological sections of the orthotopically grown primary pancreatic cancer xenografts stained with haematoxylin and eosin (H&E; right panels),
and by immunohistochemistry using anti-Ser473 Akt (left panels). Scale bar in the top left panel¼500mm.
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s(CTC-PAL; CTC Analytics, Zwingen, Switzerland). As chromato-
graphic separation matrix a RESECT Ultra Cyano reverse-phase
HPLC column (column size 50 1mm, particle size 3mm,
preceded by a guard column: Phenomenex AJO-4304 phenylpro-
pyl, size 4 2mm) was used. Gradient mobile programming was
used with a flow rate 60mlmin
 1; the mobile phase consisted of
acetonitrile and 0.2% formic acid in water (95:5). The column
eluent was directly introduced into the ion source of the triple
quadrupole mass spectrometer Quattro Micro (Micromass,
Manchester, UK) controlled by MassLynx 4.0 software. Electrospray
positive ionisation (ESI(þ)) multiple reaction monitoring was used
for the MS/MS detection of BEZ235. After ESI(þ) ionisation, the
molecular–product transitions (m/z 470.35-443.25 product ion for
BEZ235 and m/z 477.45-477.30 product ion for the IS) were
monitored for the analyte and IS respectively. The calibration
curve was prepared by adding the structurally related IS and
appropriate amounts of analyte to mouse plasma or tumour tissue
extract, covering a range from 2 to 2000ngml
 1 with LOQ set to
10ngml
 1 for plasma and 50ngg
 1 for the tumour tissue
respectively (CV and overall bias less than 30%). Regression
analysis was performed using QuanLynx 4.0 (Micromass) and
Excel 2002 (Microsoft). Concentrations of unknown samples were
calculated from the peak area ratio of the daughter ion of the
analyte to the daughter ion of its IS (ordinate) against the nominal
concentration (abscissa). Assay linearity was indicated by an
overall regression coefficient of 0.9981.
Table 1 Characterisation of the primary pancreatic cancer xenografts
Tumor ID Histological type EGFR Her2 HGFR IGF-1R p-Akt SMAD4 K-ras
OCIP16 Adenocarcinoma ++ ++ + ++ ++ +++ Codon 12 mutation
OCIP17 Poorly differentiated     ++ + +++ w/t
OCIP18 Adenocarcinoma +++ ++ ++ ++ ++   w/t
OCIP19 Adenocarcinoma ++ + + + +   Codon 12 mutation
OCIP21 Adenocarcinoma +++ +++ ++ +++ +++   w/t
w/t¼wild type.
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Figure 3 Effects of acute single doses of NVP-BEZ235 on phosphorylated Akt measured using an ELISA technique (10mg total protein per 50ml well).
Groups of animals bearing the five primary xenografts at the orthotopic site were treated with 50mgkg
 1 NVP-BEZ235 and killed at the indicated time
points.
Activity of NVP-BEZ235 against primary pancreatic cancer
P Cao et al
1270
British Journal of Cancer (2009) 100(8), 1267–1276 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sStatistics
All values are presented as mean±s.e. Comparisons between two
groups (control vs NVP-BEZ235) were achieved using the two-
tailed Student’s t-test. The criterion for statistical significance was
Po0.05.
RESULTS
Characterisation of orthotopic primary pancreatic cancer
xenografts
Histological examination of the H&E sections showed that the
primary xenografts were adenocarcinomas with features similar to
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Figure 4 Western blots of tumour lysates obtained from triplicate primary xenografts at the indicated time points following an acute single dose of
NVP-BEZ235, 50mgkg
 1,p r o b e dw i t hp r i m a r ya n t i b o d i e st o :S e r 4 7 3A k t ,S e r 2 1 / 9G S K 3 a/b, Ser235/236 S6 ribosomal protein, Thr37/46 4EBP-1, Tyr705 Stat3,
with actin loading controls. Tumour NVP-BEZ235 concentrations for each sample are indicated, with the exception of those of insufficient size for this (ND).
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sthe original surgical specimens, with the exception of OIP17 that
grew as sheets of poorly differentiated cancer cells. As seen in
Figure 2, the histological features were more complex than those
typically seen in xenografts established at the subcutaneous site
from cell lines, as has been previously noted (Rubio-Viqueira et al,
2006). The tumours tended to be moderately well differentiated,
with mucin production. They were organised into glandular
structures, with a prominent fibrovascular stroma that in some
cases comprised the bulk of the tumour. Cellular DNA content
analysis by flow cytometry confirmed that in many of these
tumours normal mouse cells accounted for 480% of the total cell
population. By immunohistochemistry, phosphorylated Akt was
readily detected in all five models (Figure 2). Staining for Ser473
Akt was also observed in the stroma of some of the xenografts, but
this was less intense that seen in the tumour tissue. Immunohis-
tochemical staining for the various growth factor receptors showed
prominent surface membrane staining for EGFR in most cases, and
variable expression of HER2 (ErbB2), c-Met (HGFR), and IGF-1R,
often with marked intra-tumoural heterogeneity in staining
intensity. The characteristics of the primary xenografts are
summarised in Table 1.
Acute single-dose effects of NVP-BEZ235
The acute single dose of 50mgkg
 1 NVP-BEZ235 administered by
oral gavage was well tolerated. The levels of Ser473 phosphorylated
PKB/Akt measured by ELISA showed considerable inter-tumoural
heterogeneity, which reflects the complex nature of these tumours
relative to subcutaneous implants of cell lines, but there was an
obvious decrease in the mean values in all five models at 2h,
followed by recovery over 24h (Figure 3). We also observed a
decrease in Ser9/21GSK3a/b levels by western blot that followed a
similar time course to p-Akt (Figure 4), consistent with inhibition
of the PI3K/Akt pathway by NVP-BEZ235 in these models. We also
found a time-dependent suppression of the downstream mTor
targets Ser235/236 S6 ribosomal protein and Thr37/46 4E-BP1 in
all five models, consistent with the action of NVP-BEZ235 as a dual
PI3K and mTor inhibitor. Similar to the ELISA data shown in
Figure 3, we observed considerable inter-tumoural heterogeneity
within the triplicate samples, which to some extent tracked
differences in the total protein levels, as shown in Supplementary
Figure 1. Phosphorylated Stat3 was readily detected in all five
models, consistent with previous reports showing aberrant
activation in pancreatic cancer cells (DeArmond et al, 2003), but
there was no significant decrease in the levels following treatment
with NVP-BEZ235 (Figure 4), suggesting that the mechanisms of
Stat3 activation are largely independent of PI3K signalling.
Tumour concentrations of NVP-BEZ235 were measured in all
of the acute single-dose samples with the exception of OCIP19,
where insufficient material was available due to their small size.
Drug concentrations were found to be in average higher at 2h
than 24h after administration (1.01 vs 0, 28.4 vs 0.50, 5.5 vs 1.44,
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Figure 5 Animal weights during chronic administration of NVP-BEZ235 or vehicle control.
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s2.1 vs 1.20nmolg
 1, for OCIP16, 18, 17, and 21 respectively;
Figure 4). These data show that different maximum concentrations
are achieved in the four models but that in all cases, the compound
is cleared form the tumour tissue with time, in agreement with the
reported mouse pharmacokinetic profile (Maira et al, 2008).
Tumour growth inhibition by NVP-BEZ235 treatment
Daily oral administration of NVP-BEZ235 at a dose of 45mgkg
 1
was well tolerated in the tumour-bearing mice. Loss of weight
occurred in the control groups of OCIP16 and 17, which was
presumably the effect of the tumours, but the other groups of
animals maintained their weight during the course of treatment
and there were no statistically significant differences in the body
weights of treated and control animals at the end of treatment in
any of the five groups (Figure 5). Because of the location of the
tumour in the orthotopic pancreas site, the tumour size was not
measured until the end of the experiments when the animals were
killed 2h after the final dose. Consequently, at the end of the 3- to
5-week treatment, orthotopic tumours were dissected free of
surrounding normal tissues and weighed. As shown in Figure 6,
NVP-BEZ235 treatment of tumour models OCIP16, 17, and 21
resulted in statistically significant delay in tumour growth (56, 36,
and 46% respectively) when compared with vehicle-treated
controls. A fourth model, OCIP19, also showed growth inhibition,
but this effect did not reach statistical significance, whereas there
was no significant growth inhibition in OCIP18. By western
blot, phosphorylated Akt and S6 were readily detected in these
tumours excised 2h after the final dose of NVP-BEZ235 (Figure 7),
although it should be noted that the sample processing was
considerably longer than that for the acute time course experiment
shown in Figure 4, which might have affected these results.
Compound concentrations in the tumour tissue 2h after last
treatment were in average of 1.11, 1.30, 0.81, and 1.16nmolg
 1,
for OCIP16, 18, 17, and 21 respectively. Hence the lack of
efficacy observed in the model OCIP18 cannot be accounted for by
a lack of exposure. NVP-BEZ235 did not show accumulation over
time in all the four tumour models tested, arguing that the efficacy
is likely due to similar effects observed after a single-dose
administration.
Effects of NVP-BEZ235 on proliferation, apoptosis, and
angiogenesis markers
To investigate the mechanisms of tumour growth inhibition by
NVP-BEZ235, the tumours were labelled for cleaved caspase 3 and
the proliferation markers cyclin D1 and p27 by immunohisto-
chemistry, and the staining intensities were measured using semi-
automated image analysis protocols. Cleaved caspase 3 showed low
levels of staining relative to that previously observed by us in
xenografts established from cell lines, and there was no significant
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Figure 6 Tumour weights at the completion of chronic dose administration. Horizontal lines indicate the mean value for each group.
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sincrease in staining in any of the primary xenograft groups treated
with NVP-BEZ235. There was a trend towards reduced labelling for
cyclin D1 in the NVP-BEZ235-treated groups (Figure 8), and this
was statistically significant in OCIP17, 19, and 21, whereas in the
non-responsive OCIP18 model there was a non-significant increase
in cyclin D1 in the NVP-BEZ235-treated animals. No significant
effects on p27 were seen in any of the five primary xenograft
models. Examination of newly formed blood vessels using CD31
staining showed that these were substantially present in the
surrounding fibrovascular stroma, rather than invading into
tumour masses. We tested several image analysis routines based
on the number of CD31-stained blood vessels, their size, and
distribution within tumour tissue and stroma. However, none of
these yielded significant changes in patterns of blood vessel
formation in any of the drug-treated tumours, relative to the
vehicle controls.
DISCUSSION
The importance of aberrant PI3K signalling in cancer has been
recognised for many years (Hennessy et al, 2005; Woodgett, 2005;
Vogt et al, 2006; Workman et al, 2006). Apart from promoting cell
growth, several signalling pathways diverge downstream from
activated PKB/Akt that suppresses apoptosis. The enhancement of
cell survival by PI3K signalling probably has a major function
during early cancer development, and has also been linked to the
high levels drug and radiation resistance seen in patients with
pancreatic cancer (Ng et al, 2001; Bondar et al, 2002; Mackenzie,
2004; Brunner et al, 2005), although it should be noted that
pancreatic cancers are heterogeneous, and the activation of
additional signalling elements, including Stat3, NFkB, and hedge-
hog pathway, is also likely to be an important determinant of
biological aggression (Bardeesy and DePinho, 2002; Arlt et al,
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s2003; DeArmond et al, 2003; Thayer et al, 2003). Experimental
PI3K inhibitors can sensitise resistant cancer cells to cytotoxic
agents or radiation, suggesting therapeutic potential in the clinic,
but until recently in vivo testing was limited due to their toxicity or
poor pharmacological properties. In contrast, the novel agent
NVP-BEZ235 has suitable drug-like properties, and is currently
been tested in phase I clinical trials in cancer patients. Given the
high prevalence of genetic changes that can drive PI3K signalling
in pancreatic cancers, we examined the pharmacodynamic and
anticancer effects of NVP-BEZ235 in a series of five recently
established primary pancreatic cancer xenografts.
Primary xenografts can be established in immune-deprived mice
from the majority of pancreatic cancer resections. Particularly
when grown at the orthotopic site, they show growth patterns
including the formation of glandular structures embedded in a
dense fibrovascular stroma that strikingly resemble those seen in
surgical samples (Capella et al, 1999; Ng et al, 2002; Rubio-
Viqueira et al, 2006). These tumours therefore appear to provide a
realistic laboratory setting in which to test novel agents for treating
a clinically intractable problem. In all models tested, acute single
doses of NVP-BEZ235 decreased the phosphorylation of PKB/Akt,
as well as its immediate downstream target GSK3, with maximum
inhibition at the 2h time point followed by recovery at 24h,
consistent with the pharmacokinetics of this compound (Maira
et al, 2008). These findings confirm that NVP-BEZ235 is able to
inhibit the activation of downstream PI3K effectors in vivo.I n
addition to its activity against class I PI3K, and like other PI3K
inhibitors, such as wortmannin and LY294002 (Brunn et al, 1996),
NVP-BEZ235 also blocks the catalytic activity of mTor. The kinase
domain of this serine/threonine kinase has a high sequence
similarity to PI3K. We observed decreases in the phosphorylation
of downstream mTor targets, particularly the S6 ribosomal protein,
that showed a similar time course to that seen with PKB/Akt
phosphorylation. These findings suggest that mTor inhibition
occurs in vivo at drug concentrations comparable to those that
inhibit PI3K.
We tested for anticancer effects of NVP-BEZ235 using daily oral
dosing, which is similar to treatment schedules commonly used in
clinical trials testing novel molecular targeted agents. The primary
end points for this part of the study were animal body and the
tumour weight at the end of the treatment period. The tumour-
bearing mice were also monitored by abdominal palpation, which
gave a rough indication of tumour growth. In a pilot study we
found that at a daily dose of 45mgkg
 1 NVP-BEZ235 was well
tolerated by the SCID mice used for the xenografts, although
weight loss occurred with more intensive treatment. This finding is
consistent with previously reported in vivo efficacy studies from
the Novartis group (Stauffer et al, 2007; Maira et al, 2008). Using
the 45mgkg
 1 daily for 5 days per week dose schedule, we did not
see increased toxicity relative to the drug vehicle control group
during the treatment period. In three of the five primary
xenografts, we observed statistically significant reduction in the
tumour size or weight relative to the drug vehicle control group,
which was consistent with the impression obtained from
abdominal palpation that oral daily treatment with NVP-BEZ235
inhibited tumour growth. Non-significant growth inhibition was
also seen in a fourth primary xenograft, OCIP19. This produced
small, slow-growing tumours, and a statistically significant effect
might have been lost due to measurement error. A fifth model,
OCIP18, was insensitive to growth inhibition by NVP-BEZ235.
Because the acute effects on PKB/Akt phosphorylation were
comparable to those seen with the other primary xenografts, the
lack of response to NVP-BEZ235 treatment is likely explained by
the activity of additional oncogenic signalling pathways in OCIP18,
rather than failure to inhibit the drug target. Perhaps relevant to
this, the levels of cyclin D1, which can be regulated by several
mechanisms downstream of PI3K/mTor, showed a decrease in all
models with the exception of OCIP18 (Figure 8).
It is likely that the use of orthotopically grown early passage
primary xenografts provides a better prediction of clinical activity,
relative to in vivo sensitivity testing based on pancreatic cancer cell
lines. Overall, the effects of NVP-BEZ235 appear less dramatic in
these models relative to those seen in xenograft established from
cell lines (Maira et al, 2008; Serra et al, 2008), which are typically
poorly differentiated and rapidly proliferating. We also failed to
show significant anti-angiogenic effects in the orthotopic primary
pancreatic cancer xenografts, which is in contrast with other
groups who have reported pronounced anti-angiogenic effects by
mTor inhibitors used to treat xenografts established from
pancreatic cancer cell lines (Azzariti et al, 2008; Manegold et al,
2008). Again, we feel that this might reflect differences in the
growth patterns seen using the orthotopic primary xenografts.
Interestingly, Schnell et al (2008) have recently shown that NVP-
BEZ235 inhibited microvessel permeability in a syngeneic rat
mammary carcinoma model, but we did not test for this effect in
the present study. Nevertheless, the response rate of 3/5 seen in the
present study appears greater than that recently reported for other
molecular targeted agents in primary pancreatic cancer xenografts
(Rubio-Viqueira et al, 2006), suggesting that dual PI3K/mTor
inhibitors like NVP-BEZ235 might have useful anticancer effects in
pancreatic cancer patients.
It remains to be determined if the daily oral dosing schedule for
NVP-BEZ235 used in this study will be optimal in the clinic.
Results from in vitro experiments suggest that the anticancer
effects of PI3K inhibitors are dependant on the extent and duration
of target inhibition. However, the acute single-dose experiments
showed that the NVP-BEZ235 dose used did not completely inhibit
PKB/Akt in tumour tissue, and the effect was of relatively short
duration. Furthermore, phosphorylated PKB/Akt was detectable in
the tumour samples obtained 2h after the final dose in the chronic
treatment group, indicating incomplete drug target inhibition. It is
unlikely that complete target inhibition could be sustained over
long periods in animal models or cancer patients, because PI3K
signalling is critical in the maintenance of normal tissues.
However, it is possible that higher doses given intermittently
might give a better therapeutic ratio by producing more complete
PI3K inhibition in the tumour, while allowing time for normal
tissue recovery.
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Figure 8 Cyclin D1 levels in tumour tissue following chronic dosing with
NVP-BEZ235 or drug vehicle, measured using immunohistochemistry and
semi-quantitative image analysis. Plots show the per cent labelled areas for
individual tumours and the mean values, together with P-values based on
unpaired two-tailed Student’s t-tests.
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sAn alternative strategy would be to combine a PI3K inhibitor
like NVP-BEZ235 with other anticancer agents. For example, we
have previously shown that this can markedly enhance sensitivity
to the standard agent gemcitabine when used in an intermittent
dose schedule (Ng et al, 2001). However, in the longer term it is
likely that synergistic interactions could be obtained combining
PI3K inhibitors with agents targeting other signalling pathways
that are aberrantly regulated in pancreatic cancers. The clinical
development of treatment protocols incorporating multiple
molecular targeted agents is problematic, because the optimum
combination would depend on the specific pattern abnormalities
in a particular cancer patient. Hence we believe that the long-term
strategy needed for an intractable problem such as pancreatic
cancer requires closer integration between basic science and
clinical oncology, including the preclinical testing based on models
similar to those used in the present study.
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